Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial

NCT05500846 | Active Not Recruiting DMC

• 2 other identifiers: CTREC-URO-181202jRCT2052210088
• Study Type: interventional
• Target: 51
• Locations: 1 country
• Sites: 2

Brief Summary

This clinical trial is to provide a minimally invasive treatment option in which the targeted prostate cancer tissue is killed by cryoablation at extremely low temperatures only in the specific area of cancer "that should be treated for saving of life"; while, leaving a portion of the normal prostate tissue that is not cancerous. It is a treatment, named by "focal therapy" for "clinically localized prostate cancer". As this new treatment is aiming to treat only specific prostatic area of cancer, it is different from the invasive conventional treatment to remove the entire prostate gland. The goal is to achieve both to control of known cancer by treating only the cancerous area and to maintain of QOL (Quality-of-life) by leaving of the other normal prostate tissue and its surrounding organs intact resulting in prevention of urinary-leakage and sexual-dysfunction as the complications.

Conditions

Prostate Cancer

Keywords

Prostate Cancer; Localized Prostate Cancer; CISca, Clinically Insignificant Prostate Cancer; CSCa, Clinically Significant Prostate Cancer; Focal Therapy; Treatment of partial prostate; Cryotherapy; Cryosurgery; Targeted Cryoablation; Ultrasound guided surgery; Targeted Prostate Biopsy; MRI, Magnetic Resonance Imaging; PSA, Prostate Specific Antigen; QOL, Quality of Life

Outcome Measures

Primary Outcomes (1)

• Disappearance of cancer at 6 month after cryosurgery evaluated by combination of the responses in PSA, MRI, and Prostate biopsy

  Achievement of all endpoints in the three clinical parameters including 1) reduction of serum PSA value, 2) reduction of PI-RADS category for MRI-visible lesion, and 3) histological disappearance of cancer by prostate biopsy 1. A 50% or greater reduction from the preoperative serum PSA level at postoperative 3 or 6 months 2. A reduction of PI-RADS category of the targeted prostate cancer lesion down to 3 or lower at MRI images at postoperative 6 months 3. No cancer tissue in histopathological examination from the targeted prostate cancer lesion via a needle biopsy of the prostate performed at postoperative 6 months

  6 months after the cryosurgery

Study Arms (1)

Cryoablation Arm

EXPERIMENTAL

Minimally invasively trans-perineal puncture of both cryo-needles and temperature-needles will be placed under real-time image guidance to the targeted area of cancer lesion or temperature-monitoring sites, respectively. The targeted tissue surrounding the tip of cryo-needles will be freeze down to targeted temperature for killing the cancer cells, and other non-treated area will be left in the prostate for aiming of maintain QOL (quality-of-life). The Minimally invasive cryoablation surgery will be performed under general anesthesia within one and half hour for aiming to be provided total 50 patients. (The used device for this arm has been clinically approved for cryoablation of renal cancer in Japan.)

Device: The Visual Ice Cryoablation System

Interventions

The Visual Ice Cryoablation System DEVICE

Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.

Also known as: Targeted focal cryoablation of localized prostate cancer

Cryoablation Arm

Eligibility Criteria

• Age: 20 Years - 85 Years
• Gender Eligibility Details: Because the prostate is an organ that only men have.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who have a PI-RADS category 3 or 4 lesion on MRI image at enrollment and who have a single lesion with a Gleason score 7 or 8 on histopathology of the prostate needle biopsy at enrollment; or, patients who have a PI-RADS category 4 or 5 lesion on MRI image at enrollment and who have a single lesion with a Gleason score 6 or 7 on histopathology of the prostate needle biopsy at enrollment
• Patients with prostate cancer that is clinical stage T2c or lower (T1a-T2cN0M0) according to the TNM Classification as determined during enrollment
• Patients between the ages of 20 and 85 when providing consent to participate in this trial
• Patients from whom consent is obtained prior to enrollment in this trial

You may not qualify if:

• Patients to have a lesion identified as PI-RADS category 4 or 5 on MRI images at enrollment and who have a single lesion with a diameter of less than 10 mm and Gleason score of 6 on the histopathology of the prostate needle biopsy at enrollment (the lesion is referred to as "non-target lesions") (the diameter of the lesion is defined as the longer one of the lesion diameter identified on MRI images at enrollment or the tumor length as measured on histopathology of prostate needle biopsy)
• Patients to have a lesion with PI-RADS category 5 on MRI image at enrollment and Gleason score 8 on histopathology of prostate needle biopsy at enrollment (the lesion is referred "excluded lesions")
• Patients with a serum prostate-specific antigen (PSA) level over 20 ng/ml during enrollment
• Patients in whom the distance from the target prostate cancer lesion to an external urinary sphincter is 5 mm or less on MRI images (coronal or sagittal) obtained during enrollment
• Patients who have undergone surgery, drug therapy, or radiation therapy for prostate cancer prior to enrollment
• Patients who have received an antiandrogen for benign prostatic hyperplasia prior to enrollment
• Patients using absorbent pads or adult diapers due to urge incontinence
• Patients with active multiple cancers
• Patients for whom MRI scans are contraindicated
• Patients in whom transrectal ultrasound cannot be performed for some reason, such as a constricted rectum
• Patients with a prothrombin time\<50% or platelet count\<60,000/mm3 during enrollment
• Patients deemed to be ineligible by an investigator

Sponsors & Collaborators

• Osamu Ukimura: lead

Study Sites (2)

University Hospital, Kyoto Prefectural University of Medicine

Kyoto, 602-8566, Japan

Location

Kyoto Miniren Chuo Hospital

Kyoto, 616-8147, Japan

Location

MeSH Terms

Conditions

Prostatic Neoplasms; Salivary Gland Adenoma, Pleomorphic

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Osamu Ukimura, M.D., Ph.D.

  Department of Urology, University Hospital, Kyoto Prefectural University of Medicine

  PRINCIPAL INVESTIGATOR

• Toshiko Ito-Ihara, M.D., Ph.D.

  The Clinical and Translational Research Center , University Hospital, Kyoto Prefectural University of Medicine (CTREC)

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor, Department of Urology

Study Record Dates

• First Submitted: August 11, 2022
• First Posted: August 15, 2022
• Study Start: October 19, 2021
• Primary Completion: November 14, 2023
• Study Completion: December 31, 2024
• Last Updated: June 21, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

JP (2)